Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
We must be getting warmer.
"Professional Travel: The Market Agrees".
"Costas Travel: We Nurture Travelling Joy"
I can picture it now.
They're all out tonight. There must be a full moon?
I detect a hint of sarcasm from Costas.
Yawn. Today's bad cop routine is tickling me pink.
Managers overseeing the junior trading desk in the Shorting Dept of Citadel don't know what a great investment they made in hiring Professional. Like a prize Wall Street bull, he is out standing in his muddy field.
Lolz
Sakura the pretend scientist is back. ...We must be getting warm!
Doc.Daneeka,
Don't assume you will be told when P2's Start.
Don't assume trials will only be in the UK.
Don't assume the clinical trial window for RSV stops dead in March - for US based trialling the NIH note that "Nationally, prepandemic seasons (2017–2020) began in October, peaked in December, and ended in April. During 2020–21, the typical winter RSV epidemic did not occur. The 2021–22 season began in May, peaked in July, and ended in January. The 2022–23 season started (June) and peaked (November) later than the 2021–22 season, but earlier than prepandemic seasons. In both prepandemic and pandemic periods, epidemics began earlier in Florida and the Southeast and later in regions further north and west. With several RSV prevention products in development,† ongoing monitoring of RSV circulation can guide the timing of RSV immunoprophylaxis and of clinical trials and postlicensure effectiveness studies. Although the timing of the 2022–23 season suggests that seasonal patterns are returning toward those observed in prepandemic years, clinicians should be aware that off-season RSV circulation might continue."
Don't assume a small targeted P2 will take a year or more to complete. Latest technology being used by the company could hasten things considerably for a highly stratified cohort. I expect months, not longer. And how much more data would an interested BP need to initiate a deal? The tipping point may be lower than you expect.
Don't assume regulatory discussions are not already well advanced.
Don't assume diagnostics required aren't already clinically available (even if not commercially...).
IMHO it is best to keep an open mind, based on best available evidence, not rush to assume worst-case scenario at every turn.
Lol. The old Halloween strategy. New-found optimism in the share from 1st Nov? Of course there is.
It could. And conversely, if we start a trial in H1 24, and it takes 3, or 6 months months to complete (wholly possible, see below*), then the timeframe will be much shorter, nowhere near as far out at 2025/26 for a commercial catalyst. (We should not underestimate how quickly small agile and highly stratified trials are now being run by BPs particularly in this current age of AI-assisted clinical trials. *Implementation of AI tools speed up clinical development by increasing the probability of trial success and regulatory approval, use adaptive protocols will increase diversity of data, while reducing trial burden on both patients and sites). We know, per what the company have told us, that the upcoming P2 trials will be smaller and more targeted than Sprinter and using latest available technology. Yes it could take until 2026, or, it could take only until 2024. You are correct in stating that we just don't know, yet.
"RM chooses to starve the shareholders of information presumably because he thinks that's the least personal risk option".
For one who claims to be so starved of information, you might want to explain who those 2 shareholders were, and how you know all about it, Spacer? Your comment seems a little... ironic.
Interested to know why you think it will take 2025 to 2026 for results of a P2 to be in Dippfs?
The company have never been tardy in reporting directorships in the past - the records @Companies House contradict what you state. Flic Gabbay, Amanada Radford,etc, all reported within the allotted time.
If Marcin Mankowski is not listed as a Director, so what? I fail to understand your point around Mankowski and a JV.
If it waddles like a duck, and it quacks like a duck, there's no point trying to convince us that it's a horse, MrC. No point whatsoever.
"sundry lawyers bringing class actions in three years’ time".
And what exactly would be the legal basis for those class action law suits Spacer? Do elaborate, if you dare.
I count only 3 posters here today (as with most days). 1 of them has more than a dozen fake accounts and is vying for the $hit-stirring award of the year in the mini LSE day-trading league. Entertaining at best. Not worth wasting intelligent discourse on, for sure.
Most interesting Alpha-Dog, than you for posting the link.
'End Off'. Exactly.
Good cop. Bad Cop. Naughty robot. Etc.
Today's posting has tickled me guys, really tickled me....
Can I suggest Spacer writes a letter of complaint to the management team at Synairgen for (a) not only not hiring HG as CFO, but also (b) not keeping him personally abreast of every operational task in their secret plan? He clearly knows what it takes to crack a multi-billion £ deal with a bevvy of BP's. I shall sleep soundly tonight knowing that Spacer is on the case. Forwards into battle, etc etc..
lol